Lupin Digital Health partners with Medicover Hospitals for post discharge cardiac care

USFDA approves Encorafenib plus Cetuximab and Chemo in BRAF V600E-positive mCRC

Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the

Glenmark USA launches Lacosamide Oral Solution, 10 mg/mL

According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million

Merck to discontinue KeyVibe and Keyform clinical trials

Merck has also decided to end the favezelimab clinical development program

Merck announces FDA acceptance of biologics license application for Clesrovimab

An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season

Kiran Mazumdar-Shaw honored by ISQ with ‘Jamsetji Tata Award’ for pioneering biosciences movement

Kiran Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman & Managing Director, TQM International

Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy

Final decision from the European Commission is anticipated within the coming months

Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio

The trademark rights for these brands will be transferred to Lupin by March next year.

Brenntag Specialties engages Esprit Care for its Southeast Asia nutraceutical market expansion

Brenntag Specialties Pharma marks a strategic milestone with its first collaboration with a contract manufacturer to enhance its nutraceutical value chain

Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase 3 trial

First and only PARP inhibitor to improve overall survival in early breast cancer